- Health & Fitness
- Medicine
- SEE MORE
- classical
- general
- talk
- News
- Family
- Bürgerfunk
- pop
- Islam
- soul
- jazz
- Comedy
- humor
- wissenschaft
- opera
- baroque
- gesellschaft
- theater
- Local
- alternative
- electro
- rock
- rap
- lifestyle
- Music
- como
- RNE
- ballads
- greek
- Buddhism
- deportes
- christian
- Technology
- piano
- djs
- Dance
- dutch
- flamenco
- social
- hope
- christian rock
- academia
- afrique
- Business
- musique
- ελληνική-μουσική
- religion
- World radio
- Zarzuela
- travel
- World
- NFL
- media
- Art
- public
- Sports
- Gospel
- st.
- baptist
- Leisure
- Kids & Family
- musical
- club
- Culture
- Health & Fitness
- True Crime
- Fiction
- children
- Society & Culture
- TV & Film
- gold
- kunst
- música
- gay
- Natural
- a
- francais
- bach
- economics
- kultur
- evangelical
- tech
- Opinion
- Government
- gaming
- College
- technik
- History
- Jesus
- Health
- movies
- radio
- services
- Church
- podcast
- Education
- international
- Transportation
- Other
- kids
- podcasts
- philadelphia
- Noticias
- love
- sport
- Salud
- film
- and
- 4chan
- Disco
- Stories
- fashion
- Arts
- interviews
- hardstyle
- entertainment
- humour
- medieval
- literature
- alma
- Cultura
- video
- TV
- Science
- en
Metastatic Hormone-Sensitive Prostate Cancer: Extending Life By Adding a Third Drug to Standard Regimens with Dr. Vincent Khoo
In this edition of OncTimes Talk we\u2019re taking a look at: extending life in patients with metastatic hormone-sensitive prostate cancer by adding a third drug to standard two-drug regimens.
\nIn the randomized Phase III ARASENS trial\u2014just published in the New England Journal of Medicine\u2014the androgen receptor inhibitor, darolutamide, was compared with placebo when added to gold-standard two-drug therapy.
\n Peter Goodwin visited the Royal Marsden Hospital in London UK to meet one of the ARASENS study investigators: Consultant Clinical Oncologist Vincent Khoo.